Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmacists Must Play More Active Role in Promoting Use of Generics
December 10, 2007
- Industry Opposed to Re-Pricing of a Wider Range of Drugs
December 10, 2007
- JGPMA Accepted as Full Member of IGPA
December 10, 2007
- Another Reduction in Medical Fees Non Recommendable: Chuikyo
December 10, 2007
- Kobashou's Shareholders Approve Share Exchange with Mediceo
December 10, 2007
- Market Price Survey Shows Average Price Gap of 6.5%
December 10, 2007
- Taisho: Switch OTC Drug Containing Ambroxol Approved
December 10, 2007
- Janssen's Prezista Included in NHI Price List
December 10, 2007
- NEW PRODUCTS／SSP to Launch S.TAC EVE FINE
December 10, 2007
- Partial Changes in Approval for Xeloda, Taxol Recommended
December 10, 2007
- NIPRO to Pursue "Development-Oriented Contract Manufacturing Business"
December 10, 2007
- Five APIs Recommended for Approval by 1st Committee on Drugs
December 10, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 10, 2007
- Eisai Submits NDA for KES524 for Obesity
December 10, 2007
- Large Gap between Korosho and Council on Views on Kongo Shinryo
December 10, 2007
- Wyeth Submits 3rd NDA This Year
December 10, 2007
- Korosho to Set Up Group to Discuss Deregulations, Kongo Shinryo
December 10, 2007
- Astellas Aims at Becoming a Global Category Leader
December 10, 2007
- REGULATORY NEWS IN BRIEF
December 10, 2007
- Ban on Kongo Shinryo Should Be Lifted: Prof. Shimada
December 10, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…